Blue Jet Healthcare
- P/E
- 39.25
Key Fundamentals
MicrocapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Standalone · TTM
- ROCE
- 26.10%
- Debt to Equity
- 0.03
- EPS (TTM)
- ₹13.55
- Book Value
- ₹114.11
- Market Cap
- —
- P/E (TTM)
- 39.25
- P/B
- 4.66
- ROE
- 19.40%
- Dividend Yield
- 0.24%
- EBITDA
- ₹215 Cr
- 52W High
- ₹647.80
- 52W Low
- ₹325.00
- Day Range
- ₹492.60 – ₹535.00
- Volume
- 4,22,928
Peer Comparison
Healthcare › Pharmaceuticals
| ₹1,773.40 | 38.81 | ₹4,29,049 Cr | 4.77 | 0.90% | 16.00% | 20.50% | ₹61,631 Cr | ₹10,987 Cr | |
| ₹10,037.50 | 91.10 | ₹2,65,269 Cr | 15.90 | 0.30% | 16.50% | 22.00% | ₹11,230 Cr | ₹2,925 Cr | |
| ₹4,738.50 | 78.61 | ₹1,77,061 Cr | 9.81 | 0.82% | 27.40% | 15.20% | ₹17,400 Cr | ₹2,099 Cr | |
| ₹1,188.10 | 26.44 | ₹1,25,446 Cr | 4.37 | 0.08% | 21.20% | 21.10% | ₹28,592 Cr | ₹4,593 Cr | |
| ₹2,323.80 | 114.81 | ₹1,25,228 Cr | 20.72 | 0.04% | 18.30% | 17.80% | ₹7,270 Cr | ₹1,090 Cr | |
| ₹1,374.00 | 35.59 | ₹1,14,543 Cr | 2.96 | 0.58% | 11.20% | 13.00% | ₹33,228 Cr | ₹3,184 Cr | |
| ₹1,402.00 | 33.59 | ₹1,12,454 Cr | 3.20 | 0.93% | 11.60% | 15.50% | ₹28,324 Cr | ₹3,356 Cr | |
| Blue Jet Healthcare (this company) | ₹531.85 | 39.25 | ₹9,569 Cr | 4.66 | 0.24% | 19.40% | 26.10% | ₹886 Cr | ₹234 Cr |
| Median 8 companies | ₹1,587.70 | 39.03 | ₹1,25,337 Cr | 4.72 | 0.44% | 17.40% | 19.15% | ₹22,862 Cr | ₹3,055 Cr |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 75
- Strong
- Returns, margins, earnings quality 22% weight
- Valuation
- 47
- Average
- Cheap vs sector & own history 24% weight
- Growth
- 2
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 82
- Strong
- Solvency, leverage, coverage 9% weight
- Momentum
- 43
- Weak
- Trend strength, vol-adjusted 12% weight
- Ownership
- 38
- Weak
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
2- Company is almost debt free.
- Company has a good return on equity (ROE) track record: 3 Years ROE 23.6%
No weaknesses listed
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Bullish | 7 | 4 | 8 |
| Oscillators | Bullish | 2 | 4 | 3 |
| Moving Averages | Neutral | 5 | 0 | 5 |
Oscillators
Bullish
Overall
Bullish
Moving Averages
Neutral
Key readings
- RSI (14)
- 54.62
- Neutral
- MACD (12,26,9)
- −11.22
- Bullish
- SMA (50)
- 545.54
- Bearish
- SMA (200)
- 487.79
- Bullish
As of
Analyst Rating
4 of 6 analysts rate Buy, 0 Hold, 2 Sell.
As of
Growth Rate
From the financial statements below. 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.
Revenue
| 5Y | +13.67% |
|---|---|
| 3Y | +9.51% |
| 1Y | −8.06% |
| TTM | −27.52% |
Net profit
| 5Y | +11.80% |
|---|---|
| 3Y | +15.73% |
| 1Y | −18.69% |
| TTM | −34.64% |
Operating cash flow
| 5Y | +19.51% |
|---|---|
| 3Y | +32.99% |
| 1Y | +626.09% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 5Y | −10.43 pp |
|---|---|
| 3Y | +0.68 pp |
| 1Y | −5.65 pp |
| TTM | −6.56 pp |
Revenue by year
| Mar 2020 | ₹538 Cr |
|---|---|
| Mar 2021 | ₹499 Cr |
| Mar 2022 | ₹683 Cr |
| Mar 2023 | ₹721 Cr |
| Mar 2024 | ₹712 Cr |
| Mar 2025 | ₹1,030 Cr |
| Mar 2026 | ₹947 Cr |
Net profit by year
| Mar 2020 | ₹145 Cr |
|---|---|
| Mar 2021 | ₹142 Cr |
| Mar 2022 | ₹182 Cr |
| Mar 2023 | ₹160 Cr |
| Mar 2024 | ₹164 Cr |
| Mar 2025 | ₹305 Cr |
| Mar 2026 | ₹248 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Blue Jet Healthcare is an almost debt-free specialty pharma intermediates company with a market cap of ~₹12,000 Cr trading at a PE of 47.9x. Revenue declined 8% on a TTM basis and net profit fell 17% YoY (FY26 PAT ₹248 Cr vs ₹305 Cr in FY25), though the company maintains a 3-year ROE of 24% and is investing ₹2,300 Cr in a greenfield facility for future growth.
- Almost debt-free balance sheet provides financial flexibility and low interest burden (interest cost just ₹6.2 Cr in FY26 on ₹332 Cr EBITDA)
- Strong 3-year ROE track record of 24% and 5-year ROE of 26%, indicating efficient capital deployment
- Contrast Media intermediates revenue grew 23% YoY in FY26 to ₹495 Cr, demonstrating diversification strength
- Q4 FY25 EBITDA margins climbed to 41%, up 1,190 bps YoY, showing operating leverage potential
- Compounded sales CAGR of 14% over 5 years reflects solid medium-term topline growth trajectory
- ₹2,300 Cr greenfield facility in Andhra Pradesh positions the company for CDMO and capacity expansion
- Gross margins improved to 54.9% in Q4 FY25, up 160 bps YoY, indicating better product mix
- Compounded profit CAGR of 16% over 3 years despite recent cyclical downturn
- TTM revenue declined 8% and FY26 revenue fell to ₹947 Cr from ₹1,030 Cr in FY25, indicating demand softness
- Net profit dropped 17% on TTM basis — FY26 PAT of ₹248 Cr vs ₹305 Cr in FY25
- Stock trades at 7.99x book value and 47.9x PE, demanding premium valuation despite earnings decline
- Working capital days increased sharply from 158 days to 224 days, signaling cash conversion deterioration
- Stock price declined 21% over the past 1 year, reflecting market skepticism on near-term growth
- Q1 FY27 revenue fell 17.7% YoY with profit down 14.2%, suggesting the downturn is continuing
- Planned ₹1,000 Cr QIP fundraise may dilute existing shareholders during a period of weak earnings
- Dividend yield of just 0.19% offers negligible income support at current valuation levels
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Blue Jet Healthcare is facing a clear earnings deterioration trend with both FY26 and Q1FY27 showing double-digit profit declines alongside falling revenues. The QIP at ₹531.70 suggests capital-raising needs, while the EcoVadis recognition and clean promoter holding structure are modest positives. The revenue contraction trend across multiple quarters is the key risk to monitor. Until top-line growth resumes, the earnings trajectory remains under pressure.
- FY26 net profit drops 18.8% Jul 6
Full-year net profit fell 18.8% to ₹2,478.16 million for FY26, with revenue declining 7.9% to ₹9,423.67 million.
- Q1FY27 profit down 14.2% YoY Aug 3
Q1FY27 net profit came in at ₹782.64 million, down 14.2% YoY, with revenue falling to ₹2,931.13 million.
- EcoVadis Silver Medal won Jul 20
Blue Jet awarded EcoVadis Silver Medal for sustainability with a score of 77, placing it in the top 15% globally.
- ₹1.2 interim dividend approved Aug 3
Board approved an interim dividend of ₹1.2 per share alongside Q1FY27 results announcement.
- QIP opened at ₹531.70 floor Jul 6
Qualified Institutions Placement opened on July 6, 2026, with a floor price of ₹531.70 per share following Board and shareholder approvals.
- Promoter confirms no encumbrance Jul 27
Akshay Bansarilal Arora and PACs confirmed zero encumbrance on their 79.81% stake per SEBI Regulation 31(4) annual disclosure for FY26.
- Q1FY27 earnings call scheduled Jul 28
Analyst and investor conference call scheduled for August 3, 2026, at 5:30 PM IST to discuss Q1FY27 unaudited standalone results.
Quarterly Results
₹ Cr| Particulars | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 180 | 181 | 167 | 184 | 163 | 208 | 318 | 340 | 355 | 165 | 192 | 235 | 293 |
| Expenses | 121 | 119 | 112 | 131 | 119 | 139 | 194 | 200 | 234 | 111 | 146 | 163 | 195 |
| Operating Profit | 59 | 63 | 55 | 53 | 44 | 69 | 124 | 140 | 121 | 55 | 47 | 71 | 98 |
| OPM % | 33% | 35% | 33% | 29% | 27% | 33% | 39% | 41% | 34% | 33% | 24% | 30% | 33% |
| Other Income | 5 | 8 | −3 | 9 | 9 | 12 | 13 | 12 | 8 | 24 | 13 | 23 | 15 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 0 | 1 | 1 |
| Depreciation | 6 | 6 | 8 | 8 | 3 | 5 | 5 | 5 | 6 | 6 | 6 | 6 | 7 |
| PBT | 58 | 64 | 44 | 54 | 49 | 77 | 132 | 147 | 123 | 69 | 54 | 87 | 106 |
| Tax % | 24% | 26% | 27% | 27% | 24% | 24% | 25% | 25% | 26% | 24% | 25% | 26% | 26% |
| Net Profit | 44 | 48 | 32 | 39.49 | 38 | 58 | 99 | 110 | 91 | 52 | 40 | 64 | 78 |
| EPS (₹) | 2.54 | 2.76 | 1.85 | 2.29 | 2.18 | 3.36 | 5.71 | 6.35 | 5.26 | 3.01 | 2.32 | 3.71 | 4.51 |
Profit & Loss
₹ Cr| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|
| Sales | 538 | 499 | 683 | 721 | 712 | 1,030 | 947 | 886 |
| Expenses | 325 | 292 | 434 | 502 | 481 | 652 | 653 | 614 |
| Operating Profit | 214 | 207 | 249 | 219 | 231 | 378 | 294 | 271 |
| OPM % | 40% | 41% | 36% | 30% | 32% | 37% | 31% | 31% |
| Other Income | 6 | 9 | 19 | 24 | 18 | 46 | 69 | 76 |
| Interest | 7 | 5 | 3 | 1 | 0 | 0 | 6 | 6 |
| Depreciation | 18 | 20 | 22 | 25 | 28 | 18 | 24 | 25 |
| PBT | 194 | 190 | 243 | 217 | 220 | 406 | 333 | 316 |
| Tax % | 25% | 26% | 25% | 26% | 26% | 25% | 25% | — |
| Net Profit | 145 | 142 | 182 | 160 | 164 | 305 | 248 | 235 |
| EPS (₹) | Not comparable with later periods: it is stated on a share count about a hundred times or more different, so it is left blank. | Not comparable with later periods: it is stated on a share count about a hundred times or more different, so it is left blank. | 10.47 | 9.23 | 9.44 | 17.59 | 14.29 | 13.55 |
| Div. Payout % | 0% | 0% | 0% | 0% | 11% | 7% | 8% | — |
Balance Sheet
₹ Cr| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Equity Capital | 0.6 | 10 | 35 | 35 | 35 | 35 | 35 |
| Reserves | 198 | 330 | 487 | 647 | 811 | 1,098 | 1,325 |
| Borrowings | 74 | 52 | 19 | 5 | 3 | 21 | 44 |
| Other Liabilities | 92 | 142 | 173 | 176 | 211 | 263 | 238 |
| Total Liabilities | 364 | 534 | 713 | 862 | 1,059 | 1,418 | 1,641 |
| Fixed Assets | 107 | 139 | 156 | 151 | 172 | 300 | 316 |
| CWIP | 2 | 3 | 3 | 30 | 147 | 89 | 301 |
| Investments | 26 | 37 | 94 | 189 | 250 | 187 | 252 |
| Other Assets | 229 | 355 | 460 | 491 | 489 | 841 | 771 |
| Total Assets | 364 | 534 | 713 | 862 | 1,059 | 1,418 | 1,641 |
Cash Flow
₹ Cr| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Operating | 122 | 137 | 146 | 142 | 241 | 46 | 334 |
| Investing | −45 | −61 | −76 | −147 | −264 | −35 | −276 |
| Financing | −72 | −21 | −56 | −4 | −2 | −19 | −31 |
| Net Cash Flow | 5 | 55 | 14 | −10 | −24 | −8 | 28 |
| Free Cash Flow | 106 | 85 | 125 | 83 | 68 | −34 | 115 |
| CFO/OP | 80 | 66 | 70 | 92 | 109 | 36 | 151 |
Ratios
| Particulars | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|
| Debtor Days | 80 | 105 | 121 | 121 | 91 | 124 | 131 |
| Inventory Days | 120 | 253 | 133 | 137 | 151 | 209 | 157 |
| Days Payable | 90 | 128 | 72 | 58 | 35 | 70 | 48 |
| Cash Conversion Cycle | 110 | 231 | 183 | 199 | 206 | 262 | 240 |
| Working Capital Days | 55 | 89 | 103 | 120 | 92 | 157 | 136 |
| ROCE % | — | 58% | 53% | 35% | 30% | 40% | 26% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Blue Jet Healthcare insights
71 extracted metrics across FY20–FY27.
Documents
- Q1 FY27 concall · Aug 2026Transcript PPT Recording
- Q4 FY26 concall · May 2026Transcript PPT Recording
- Q3 FY26 concall · Feb 2026Transcript PPT Recording
- Q2 FY26 concall · Nov 2025Transcript PPT Recording
- Q1 FY26 concall · Jul 2025Transcript PPT Recording
- 25 May 2026
- 13 Feb 2026
- 22 Jul 2025
- 16 Dec 2025
- General announcements 29 Oct 2026
- General announcements 8 Oct 2026
Frequently Asked Questions about Blue Jet Healthcare
What does Blue Jet Healthcare Ltd do?
Where is Blue Jet Healthcare Ltd (BLUEJET) listed?
Which sector does Blue Jet Healthcare Ltd belong to?
What is the PE ratio of Blue Jet Healthcare Ltd?
What is the 52-week high and low of Blue Jet Healthcare Ltd?
Does Blue Jet Healthcare Ltd pay dividends?
What is the Return on Equity (ROE) of Blue Jet Healthcare Ltd?
Company Information
Incorporated in 1968, Blue Jet Healthcare (earlier called Jet Chemicals Pvt Ltd) is a pharmaceutical and healthcare ingredient & intermediate company and the first manufacturer of saccharin and its salts (artificial sweeteners) in India.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/BLUEJET.md for Blue Jet Healthcare Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.